In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding
Annals of Internal Medicine · 2023
DOI: 10.7326/j23-0090 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Manasi Tannu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Duke University School of Medicine, Durham, North Carolina, USA (M.T., L.K.N.). Hauptthemen laut MEDLINE: Aspirin, Percutaneous Coronary Intervention.
Abstract (Originalsprache)
SOURCE CITATION: Gragnano F, Cao D, Pirondini L, et al; PANTHER Collaboration. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol. 2023;82:89-105. 37407118.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke University School of Medicine, Durham, North Carolina, USA (M.T., L.K.N.).
Zitieren
APA
Tannu, M., & Newby, L. K. (2023). In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding. Annals of Internal Medicine. https://doi.org/10.7326/j23-0090
Vancouver
Tannu M, Newby LK. In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding. Annals of Internal Medicine. 2023. doi:10.7326/j23-0090
BibTeX
@article{Tannu2023,
author = {Tannu, Manasi and Newby, L Kristin},
title = {In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j23-0090}
}
EUVIMED